Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

KROS

Keros Therapeutics Inc

May 13 • 04:00PM ET

11.99

+0.34 2.92 %

Healthcare • Biotechnology • USA • Micro • NASD

Peers: SRRK MREO ABEO LRMR RIGL

| Held by: IWM VTI IWN VXF BSVO VTWO IBB AVUV SCHA DFSV

Index	RUT	P/E	6.58	EPS (ttm)	1.82	Insider Own	8.72%	Shs Outstand	19.54M	Perf Week	1.78%
Market Cap	237.26M	Forward P/E	-	EPS next Y	-4.78	Insider Trans	-1.00%	Shs Float	18.06M	Perf Month	3.81%
Enterprise Value	-33.28M	PEG	-	EPS next Q	-1.02	Inst Own	100.83%	Short Float	7.84%	Perf Quarter	-29.64%
Income	87.01M	P/S	0.97	EPS this Y	-309.44%	Inst Trans	-51.98%	Short Ratio	3.41	Perf Half Y	-29.64%
Sales	244.06M	P/B	0.77	EPS next Y	0.71%	ROA	18.15%	Short Interest	1.42M	Perf YTD	-41.11%
Book/sh	15.51	P/C	0.83	EPS next 5Y	-	ROE	19.90%	52W High	22.55 -46.83%	Perf Year	-10.99%
Cash/sh	14.52	P/FCF	2.24	EPS past 3/5Y	- -	ROIC	27.40%	52W Low	10.41 15.12%	Perf 3Y	-73.33%
Dividend Est.	-	EV/EBITDA	-0.48	Sales past 3/5Y	- -	Gross Margin	99.38%	Volatility	5.47% 3.71%	Perf 5Y	-74.11%
Dividend TTM	-	EV/Sales	-0.14	EPS Y/Y TTM	137.16%	Oper. Margin	27.72%	ATR (14)	0.52	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	15.45	Sales Y/Y TTM	6774.96%	Profit Margin	35.65%	RSI (14)	54.02	Recom	1.86
Dividend Gr. 3/5Y	- -	Current Ratio	15.45	EPS Q/Q	24.40%	SMA20	3.55%	Beta	0.96	Target Price	22.20
Payout	0.00%	Debt/Eq	0.06	Sales Q/Q	-87.34%	SMA50	4.19%	Rel Volume	0.83	Prev Close	11.65
Employees	78	LT Debt/Eq	0.05	Earnings	Mar 04 AMC	SMA200	-22.47%	Avg Volume	415.22K	Price	11.99
IPO	Apr 08, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-23.37% -89.50%	Trades		Volume	345,655	Change	2.92%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Initiated	Wells Fargo	Overweight	$26
Jun-10-25	Downgrade	BofA Securities	Buy → Neutral	$18
Jan-21-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-17-25	Downgrade	Wedbush	Outperform → Neutral	$15
Dec-16-24	Reiterated	Oppenheimer	Outperform	$102 → $63
Dec-16-24	Downgrade	Guggenheim	Buy → Neutral
Dec-13-24	Reiterated	H.C. Wainwright	Buy	$100 → $47
Dec-12-24	Downgrade	William Blair	Outperform → Mkt Perform
Dec-12-24	Downgrade	TD Cowen	Buy → Hold
Dec-12-24	Downgrade	BTIG Research	Buy → Neutral
Nov-05-24	Initiated	Jefferies	Buy
Oct-24-24	Initiated	Cantor Fitzgerald	Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-23-24	Initiated	Guggenheim	Buy	$96
Jun-25-24	Initiated	Oppenheimer	Outperform	$102
Feb-21-24	Initiated	William Blair	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight	$60
Jul-31-23	Initiated	Wedbush	Outperform	$86
Jul-26-23	Initiated	BofA Securities	Buy	$65
Feb-14-23	Initiated	Cowen	Outperform

Show Previous Ratings

Mar-09-26 08:00AM	Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference (GlobeNewswire)
08:00AM	Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS (GlobeNewswire)
Mar-06-26 11:57AM	Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market? (Zacks)
Mar-05-26 12:53PM	Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline? (Zacks) -14.96%
Mar-04-26 05:10PM	Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Loading…
04:01PM	Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-28-26 12:35PM	Keros Therapeutics Touts Rinvatercept DMD Trial Start, Eyes ALS Phase II Talks at Oppenheimer Conference (MarketBeat)
Feb-26-26 04:01PM	Keros Therapeutics Appoints Charles Newton to its Board of Directors (GlobeNewswire) -5.59%
Feb-18-26 04:01PM	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences (GlobeNewswire)
09:39AM	Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? (Zacks)
Feb-03-26 11:39AM	Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results? (Zacks)
Jan-27-26 10:50AM	SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD (Zacks)
09:16AM	Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? (Zacks)
Jan-26-26 09:15AM	Is KROS' KER-065 the Next Breakthrough in DMD Space? (Zacks)
Jan-23-26 07:18AM	JANX Enters Global Oncology Collaboration With BMY, Stock Rises (Zacks)
11:55AM	Loading…
Jan-22-26 11:55AM	Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema (Zacks)
Jan-21-26 08:36AM	MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know (Zacks)
Jan-19-26 12:53PM	Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease (Zacks)
Jan-16-26 11:15AM	Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia (Zacks)
09:08AM	Will KROS Stock's Restructuring Efforts Reap Rewards for Investors? (Zacks)
Jan-15-26 10:26AM	CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why (Zacks)
09:14AM	KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? (Zacks)
Jan-14-26 10:54AM	TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA (Zacks)
10:52AM	TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results (Zacks)
Jan-13-26 01:00PM	BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises (Zacks)
Jan-12-26 09:32AM	INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced (Zacks)
Jan-08-26 12:33PM	GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies (Zacks)
Jan-02-26 12:41PM	This Health Name Gains Over 400% In 2025. A Gold Stock Is Right Behind It. (Investor's Business Daily) -8.94%
04:32AM	Zacks.com featured highlights include AES, BorgWarner, Enersys, PG&E and Keros Therapeutics (Zacks)
Dec-31-25 07:33AM	5 Low Price-to-Book Stocks to Buy as 2025 Comes to a Close (Zacks)
11:40AM	Loading…
Dec-30-25 11:40AM	KROS or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
Dec-22-25 12:00PM	Keros Therapeutics (KROS) Upgraded to Strong Buy: Here's Why (Zacks) +5.33%
09:55AM	Here's Why Keros Therapeutics (KROS) Could be Great Choice for a Bottom Fisher (Zacks)
Dec-16-25 09:23AM	5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 (Zacks)
04:02AM	Zacks.com featured highlights include StoneCo, General Motors, Enersys, Deutsche, Keros (Zacks)
Dec-15-25 09:14AM	Buy These 5 Best Value Stocks to Boost Your Portfolio in December (Zacks)
Dec-12-25 12:00PM	What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now? (Zacks)
11:40AM	KROS vs. ARGX: Which Stock Is the Better Value Option? (Zacks)
Nov-28-25 09:53AM	Buy These 5 Best Value Stocks to Make the Most of P/B Ratio (Zacks)
Nov-26-25 11:40AM	KROS or NVZMY: Which Is the Better Value Stock Right Now? (Zacks)
09:55AM	How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% (Zacks)
Nov-20-25 04:01PM	Keros Therapeutics Announces Final Results of Tender Offer (GlobeNewswire)
Nov-19-25 06:00AM	Keros Therapeutics Announces Preliminary Results of Tender Offer (GlobeNewswire)
Nov-13-25 07:34AM	5 Undervalued Stocks That Are Poised for Growth in November (Zacks)
Nov-10-25 11:40AM	KROS vs. ARGX: Which Stock Is the Better Value Option? (Zacks) +5.19%
09:55AM	Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High? (Zacks)
Nov-05-25 05:40PM	Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Keros Therapeutics Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-21-25 09:43AM	Keros Therapeutics (KROS) Moves 9.8% Higher: Will This Strength Last? (Zacks)
Oct-20-25 06:00AM	Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares (GlobeNewswire) +9.83%
Oct-15-25 06:30AM	Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital (GlobeNewswire)
Sep-08-25 08:00AM	Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting (GlobeNewswire)
Aug-28-25 04:01PM	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences (GlobeNewswire)
Aug-21-25 08:30AM	ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment (PR Newswire) +6.61%
06:56AM	Keros gains FDA orphan drug status for DMD treatment KER-065 (Pharmaceutical Technology)
Aug-20-25 09:48AM	Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Aug-06-25 05:45PM	Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -7.29%
04:15PM	Keros to Exclusively Prioritize the Clinical Advancement of KER-065 (GlobeNewswire)
04:01PM	Keros Therapeutics Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-28-25 11:40AM	KROS vs. EXAS: Which Stock Should Value Investors Buy Now? (Zacks)
Jul-23-25 10:54AM	Will Reblozyl Enable BMY to Offset the Impact of Generic Competition? (Zacks) +5.10%
Jul-18-25 11:28AM	RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure (Zacks)
10:39AM	FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo (Zacks)
Jul-17-25 08:00AM	Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept (GlobeNewswire)
Jul-10-25 12:10PM	KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up (Zacks)
11:09AM	RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data (Zacks)
Jun-11-25 09:40AM	McDonalds downgraded on GLP-1 drug worries: Wall Streets top analyst calls (TipRanks)
Jun-10-25 02:37PM	Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst (Benzinga)
Jun-09-25 03:12PM	ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal (PR Newswire) -6.32%
06:55AM	Keros Announces Return of $375 Million in Excess Capital to Stockholders (GlobeNewswire)
Jun-06-25 04:01PM	Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-30-25 06:36AM	Keros lays off nearly half its staff; Astellas buys into a China biotechs ADC (BioPharma Dive)
May-29-25 11:24PM	Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial (Insider Monkey)
12:54PM	Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45% (Benzinga)
06:55AM	Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring (GlobeNewswire)
May-27-25 01:45PM	Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "FOR" All of Keros' Director Nominees (GlobeNewswire)
May-21-25 08:00AM	ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth (PR Newswire)
May-19-25 08:00AM	Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value (GlobeNewswire)
May-12-25 12:11PM	ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth (PR Newswire)
08:00AM	Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference (GlobeNewswire)
May-08-25 05:31PM	Keros Reinforces Commitment to Maximizing Stockholder Value (GlobeNewswire)
02:10PM	ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders (PR Newswire)
May-06-25 07:10PM	Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates (Zacks) -5.46%
04:01PM	Keros Therapeutics Reports Recent First Quarter 2025 Financial Results (GlobeNewswire)
May-05-25 05:10PM	Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-02-25 08:40AM	Implied Volatility Surging for Keros Therapeutics Stock Options (Zacks)
Apr-11-25 02:13PM	Keros Therapeutics: Strategic Alternatives Could Bring About Value Creation (Seeking Alpha)
12:05PM	Prada to acquire Versace, CarMax reports mixed Q4 results: Morning Buzz (TipRanks)
11:57AM	KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5% (Zacks)
Apr-10-25 12:58PM	Keros Therapeutics considers sale amid investor pressure (Pharmaceutical Technology) +18.49%
06:00AM	Keros Therapeutics Announces Review of Strategic Alternatives (GlobeNewswire)
Mar-31-25 06:00AM	Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers (GlobeNewswire) -5.56%
Mar-21-25 09:55AM	Wall Street Analysts Think Keros Therapeutics (KROS) Could Surge 156.99%: Read This Before Placing a Bet (Zacks)
Mar-05-25 09:55AM	Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade (Zacks)
Feb-28-25 05:00PM	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences (GlobeNewswire)
Feb-26-25 05:10PM	Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Jan-30-25 08:00AM	Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-22-25 08:53AM	Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock? (Zacks)
Jan-21-25 08:00AM	Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept (GlobeNewswire) +5.06%

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BIENAIME JEAN JACQUES	Director	Apr 15 '26	Buy	11.70	1,000	11,700	8,450	Apr 17 04:15 PM
Seehra Jasbir	CHIEF EXECUTIVE OFFICER	Apr 02 '26	Option Exercise	0.30	55,000	16,500	440,708	Apr 06 04:15 PM
OrbiMed Genesis Master Fund, L	Shareholder	Mar 31 '26	Proposed Sale	11.04	45,057	497,429		Mar 31 09:57 PM
BIENAIME JEAN JACQUES	Director	Mar 09 '26	Buy	11.21	2,000	22,420	7,450	Mar 11 04:33 PM
Seehra Jasbir	CHIEF EXECUTIVE OFFICER	Feb 19 '26	Sale	16.17	7,015	113,433	385,708	Feb 20 04:15 PM
Lerner Lorena Raquel	Chief Science Officer	Feb 18 '26	Sale	16.35	3,873	63,324	31,127	Feb 20 04:15 PM
Cho Esther	SVP, General Counsel	Feb 18 '26	Sale	16.35	4,745	77,581	39,755	Feb 20 04:15 PM
Regnante Keith	CHIEF FINANCIAL OFFICER	Feb 18 '26	Sale	16.35	4,739	77,483	39,261	Feb 20 04:15 PM
Pontifax Management 4 G.P. (20	10% Owner	Oct 15 '25	Sale	17.75	4,787,331	84,975,125	0	Oct 17 05:53 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 15 '25	Sale	17.75	5,389,264	95,659,436	0	Oct 15 01:24 PM
Rovaldi Christopher	Affiliate	Sep 12 '25	Proposed Sale	15.71	85,306	1,340,157		Sep 12 04:45 PM

Open in Screener

IMNM

Immunome Inc

May 13 • 04:00PM ET

22.20

-0.49 -2.16 %

Healthcare • Biotechnology • USA • Mid • NASD

Peers: IOVA ABCL KYMR NRIX SNDX

| Held by: XBI VTI IWM VXF IWO SCHA VTWO CANC VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-2.38	Insider Own	9.24%	Shs Outstand	113.17M	Perf Week	-4.60%
Market Cap	2.51B	Forward P/E	-	EPS next Y	-2.09	Insider Trans	-3.92%	Shs Float	102.68M	Perf Month	-3.06%
Enterprise Value	1.94B	PEG	-	EPS next Q	-0.54	Inst Own	98.14%	Short Float	18.17%	Perf Quarter	-5.17%
Income	-224.59M	P/S	626.97	EPS this Y	7.05%	Inst Trans	25.21%	Short Ratio	16.34	Perf Half Y	35.04%
Sales	4.01M	P/B	4.27	EPS next Y	7.33%	ROA	-46.67%	Short Interest	18.66M	Perf YTD	3.35%
Book/sh	5.20	P/C	4.31	EPS next 5Y	24.18%	ROE	-50.14%	52W High	27.65 -19.71%	Perf Year	180.66%
Cash/sh	5.15	P/FCF	-	EPS past 3/5Y	7.72% -7.71%	ROIC	-37.91%	52W Low	7.42 199.19%	Perf 3Y	225.04%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	25.73%	Volatility	5.38% 4.62%	Perf 5Y	35.95%
Dividend TTM	-	EV/Sales	482.58	EPS Y/Y TTM	53.10%	Oper. Margin	-5698.83%	ATR (14)	1.14	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	21.68	Sales Y/Y TTM	-63.29%	Profit Margin	-5593.85%	RSI (14)	45.61	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	21.68	EPS Q/Q	9.25%	SMA20	-4.39%	Beta	2.09	Target Price	35.77
Payout	-	Debt/Eq	0.01	Sales Q/Q	-100.00%	SMA50	0.74%	Rel Volume	0.90	Prev Close	22.69
Employees	177	LT Debt/Eq	0.01	Earnings	May 12 AMC	SMA200	22.64%	Avg Volume	1.14M	Price	22.20
IPO	Oct 02, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	13.70% -100.00%	Trades		Volume	1,030,477	Change	-2.16%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-12-26	Initiated	H.C. Wainwright	Buy	$40
Dec-01-25	Initiated	Truist	Buy	$36
Sep-22-25	Initiated	Goldman	Buy	$26
Sep-05-25	Initiated	Craig Hallum	Buy	$26
Apr-02-25	Initiated	Lake Street	Buy	$23
Nov-08-24	Initiated	Stephens	Overweight	$30
May-31-24	Initiated	Piper Sandler	Overweight	$27
Apr-30-24	Initiated	JP Morgan	Overweight	$24
Apr-15-24	Initiated	Guggenheim	Buy	$35
Jan-29-24	Initiated	Leerink Partners	Outperform	$30
Dec-19-23	Initiated	Wedbush	Outperform	$12
Oct-29-21	Initiated	Cantor Fitzgerald	Overweight	$35

Show Previous Ratings

May-12-26 04:02PM	Immunome Reports First Quarter 2026 Financial Results and Provides Business Update (Business Wire)
May-05-26 04:00PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-29-26 07:30AM	Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors (Business Wire)
Apr-21-26 10:30AM	Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting (Business Wire)
Apr-02-26 04:00PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:00PM	Loading…
Mar-05-26 04:00PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.97%
Mar-03-26 04:02PM	Immunome Reports Full Year 2025 Financial Results and Provides Business Update (Business Wire)
Mar-02-26 02:57AM	Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development (Insider Monkey)
Feb-23-26 08:00AM	Immunome to Present at Upcoming Investor Conferences (Business Wire)
Feb-13-26 11:03PM	Immunome CEO Touts Phase 3 Desmoid Win, Near-Term FDA NDA Plan and Early IM-1021 ADC Responses (MarketBeat)
Feb-12-26 09:44AM	Shopify upgraded, Coinbase downgraded: Wall Street's top analyst calls (The Fly)
08:00AM	Here Are Thursdays Top Wall Street Analyst Research Calls: BP Plc., Borg Warner, Generac, Kraft-Heinz, MercadoLibre, Pfizer, Shopify, Valvoline, and More (24/7 Wall St.)
Feb-05-26 04:00PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.13%
Feb-04-26 08:00AM	Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (Business Wire)
Jan-15-26 11:35AM	Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now? (Insider Monkey) +10.07%
04:05PM	Loading…
Jan-08-26 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
07:45AM	Jim Cramer on Immunome: "If You Want to Speculate on It, Fine" (Insider Monkey)
Jan-06-26 08:00AM	Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-05-26 08:05PM	Lightning Round: Nokia is up against a lot of tough companies, says Jim Cramer (CNBC TV) -5.33%
Dec-16-25 08:16PM	Immunome Announces Pricing of Public Offering of Common Stock (Business Wire) -15.76%
07:26AM	Immunome seeks GSI inhibitor market entry on Phase III desmoid tumour win (Clinical Trials Arena)
Dec-15-25 06:03PM	Why Immunome Stock Surged Today (Motley Fool) +15.69%
04:36PM	Stocks Fall Ahead of US November Payroll Report (Barchart)
04:34PM	Immunome, A Top 3% Stock, Just Delivered A 'Knockout' To Merck KGaA (Investor's Business Daily)
04:01PM	Immunome Announces Proposed Public Offering of Common Stock (Business Wire)
12:53PM	Stock Market Today: Russell 2000, Nasdaq Decline After Strong Start to Trading Week (TheStreet)
07:00AM	Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors (Business Wire)
Dec-14-25 04:00PM	Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors (Business Wire)
Dec-04-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-25-25 08:00AM	Immunome to Present at Upcoming Investor Conferences (Business Wire)
04:05PM	Loading…
Nov-06-25 04:05PM	Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Nov-04-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.35%
Oct-31-25 11:51AM	Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference (Business Wire)
Oct-23-25 12:00PM	Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance (Business Wire)
Oct-02-25 05:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.93%
Sep-25-25 06:30AM	Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains? (Zacks) -9.33%
Sep-18-25 08:00AM	Infinimmune Announces Research Collaboration with Immunome (Business Wire) +9.57%
Sep-04-25 05:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.35%
Sep-03-25 08:00AM	Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire) +10.45%
Aug-22-25 09:35AM	Gap downgraded, Ulta upgraded: Wall Street's top analyst calls (The Fly)
Aug-06-25 05:45PM	Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -5.64%
05:30PM	Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
10:00AM	Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
07:00AM	OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee (GlobeNewswire)
Aug-05-25 05:15PM	Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-01-25 05:51PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-03-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-01-25 10:29AM	Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock? (Zacks) -8.98%
Jun-16-25 12:00PM	Immunome (IMNM) Upgraded to Buy: Here's What You Should Know (Zacks)
Jun-12-25 09:55AM	Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High? (Zacks)
Jun-05-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-26-25 09:55AM	Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet (Zacks)
May-22-25 08:00AM	Immunome to Present at Upcoming Investor Conferences (Business Wire) +6.82%
May-13-25 12:00PM	All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy (Zacks)
May-12-25 05:45PM	Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.43%
05:25PM	Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Immunome Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
May-08-25 09:55AM	Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade (Zacks)
May-02-25 04:01PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-17-25 06:06AM	Immunome: Transformed Pipeline Offers Multiple Catalysts (Seeking Alpha) +10.32%
Apr-10-25 09:32AM	Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last? (Zacks)
Apr-04-25 08:00AM	Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference (Business Wire)
Apr-03-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.00%
Mar-26-25 08:00PM	Closing Bell Movers: GameStop gains 7% on earnings, bitcoin announcement (TipRanks)
Mar-19-25 05:35PM	Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Immunome Reports Full Year 2024 Financial Results and Provides Business Update (Business Wire)
Mar-10-25 07:41AM	Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC (Business Wire) -5.25%
Mar-06-25 04:01PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-25-25 08:00AM	Immunome to Present at Upcoming March Conferences (Business Wire)
Feb-06-25 04:01PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-31-25 04:01PM	Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (Business Wire) -6.44%
Jan-29-25 11:11PM	Immunome Announces Pricing of Upsized Public Offering of Common Stock (Business Wire) +12.41%
04:27PM	Immunome Announces Proposed Public Offering of Common Stock (Business Wire)
Jan-13-25 08:00AM	Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) -5.28%
Jan-07-25 08:00AM	Hummingbird Bioscience Licenses Novel Antibodies to Immunome (GlobeNewswire)
Jan-02-25 06:03PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.03%
Dec-02-24 06:26PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-27-24 01:22PM	Hedge Fund and Insider Trading News: Scott Bessent, Paloma Partners, Taula Capital Management, Immunome Inc (IMNM), AppLovin Corp (APP), and More (Insider Monkey) +16.83%
08:00AM	Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference (Business Wire)
Nov-13-24 05:15PM	Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -7.21%
04:05PM	Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Nov-05-24 08:00AM	Immunome to Present at Guggenheims Inaugural Healthcare Innovation Conference (Business Wire)
Nov-01-24 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +10.53%
Oct-30-24 08:30AM	Immunome Advances with Strategic Asset Acquisition and Agreement (TipRanks)
Oct-29-24 08:00AM	Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021 (Business Wire)
Oct-18-24 08:00AM	Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium (Business Wire)
Oct-08-24 08:05AM	Immunome Appoints Roee Shahar as Executive Vice President, Commercial (Business Wire)
08:00AM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-13-24 07:00AM	Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 (Business Wire) +8.57%
Aug-29-24 08:00AM	Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-20-24 03:26PM	Immunome Stock Sees RS Rating Jump To 91 (Investor's Business Daily) +6.36%
Aug-12-24 05:15PM	Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +7.04%
04:01PM	Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-25-24 08:00AM	Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities (Business Wire) +5.67%
07:30AM	Nectin Therapeutics Licenses Novel Antibodies to Immunome (PR Newswire)
Jul-09-24 07:00AM	STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors (GlobeNewswire)
Jun-27-24 08:00AM	Immunome Appoints Phil Tsai as Chief Technical Officer (Business Wire)
May-22-24 02:05PM	Hedge Fund and Insider Trading News: David Tepper, Stanley Druckenmiller, Oaktree Capital Management, Odey Asset Management, ProFrac Holding Corp. (ACDC), Immunome Inc (IMNM), and More (Insider Monkey) +5.64%
May-21-24 07:01PM	Insider Buying: Immunome Inc's CEO Acquires 100,000 Shares (GuruFocus.com)

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Higgins Jack	Chief Scientific Officer	Apr 02 '26	Sale	21.64	9,438	204,238	22,000	Apr 03 07:48 PM
Rosett Max	Chief Financial Officer	Apr 02 '26	Option Exercise	1.22	71,561	87,053	119,037	Apr 03 07:46 PM
Rosett Max	Chief Financial Officer	Apr 02 '26	Sale	21.92	65,000	1,424,916	54,037	Apr 03 07:46 PM
Rosett Max	Officer	Apr 02 '26	Proposed Sale	72.67	65,000	4,723,550		Apr 02 11:46 AM
Higgins Jack	Officer	Apr 02 '26	Proposed Sale	21.64	9,438	204,238		Apr 02 11:32 AM
SIEGALL CLAY B	President and CEO	Mar 27 '26	Buy	19.67	25,450	500,602	690,704	Mar 31 07:11 AM
WAGENHEIM PHILIP	Director	Mar 20 '26	Sale	20.47	36,800	753,296	369,347	Mar 23 09:23 PM
WAGENHEIM PHILIP	Director	Mar 23 '26	Sale	20.65	28,200	582,330	341,147	Mar 23 09:23 PM
WAGENHEIM PHILIP	Director	Mar 20 '26	Proposed Sale	20.81	65,000	1,352,640		Mar 20 12:56 PM
BIENAIME JEAN JACQUES	Director	Mar 10 '26	Buy	22.12	1,000	22,120	37,415	Mar 12 06:05 AM
BIENAIME JEAN JACQUES	Director	Mar 11 '26	Buy	21.55	1,000	21,550	38,415	Mar 12 06:05 AM
SIEGALL CLAY B	President and CEO	Dec 30 '25	Buy	21.15	4,729	100,018	665,254	Dec 30 06:47 PM
Barchas Isaac	Director	Dec 22 '25	Sale	21.74	383,200	8,330,080	2,031,181	Dec 23 04:41 PM
SIEGALL CLAY B	President and CEO	Dec 19 '25	Buy	20.48	7,278	149,053	860,525	Dec 22 07:38 AM
Tsai Philip	Chief Technical Officer	Dec 19 '25	Buy	20.49	10,000	204,900	43,300	Dec 22 07:32 AM
SIEGALL CLAY B	President and CEO	Dec 18 '25	Buy	21.50	46,511	999,986	853,247	Dec 18 05:03 PM
Higgins Jack	Chief Scientific Officer	Sep 10 '25	Option Exercise	1.35	22,000	29,700	40,729	Sep 11 09:04 PM
BIENAIME JEAN JACQUES	Director	Jun 03 '25	Buy	9.38	5,000	46,900	36,415	Jun 03 09:21 PM

KROS

Keros Therapeutics Inc

IMNM

Immunome Inc

Upgrade your Finviz experience